Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 20/20 | 0.77 |
| ▸ | CYBB | P04839 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615058 | 0.87 | NOX4 (1.00) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL31511711 | 0.87 | NOX4 (1.00) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL1723441 | 0.85 | NOX4 (1.00) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL30637790 | 0.85 | NOX4 (1.00) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL2214964 | 0.85 | NOX4 (1.00) | NOX4CYBBCYP3A4NOX1 | |
| Hydrochloric Acid SCHEMBL29430193 | 0.84 | NOX4 (0.98) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL3614947 | 0.83 | NOX4 (0.84) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL2208995 | 0.83 | NOX4 (1.00) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL2213178 | 0.81 | NOX4 (0.91) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL2220173 | 0.81 | NOX4 (1.00) | NOX4CYBBCYP3A4NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914910-B2 | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2018-03-13 | — | — | US | claimed |
| US-20170275591-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL | 2017-09-28 | — | — | US | claimed |
| US-20160010061-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL | 2016-01-14 | — | — | US | claimed |
| WO-2014153227-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2014-09-25 | — | — | WO | claimed |
| US-9914910-B2 | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914910-B2 | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914910-B2 | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170275591-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL | 2017-09-28 | — | — | US | disclosed |
| US-20170275591-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL | 2017-09-28 | — | — | US | disclosed |
| US-20170275591-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL | 2017-09-28 | — | — | US | disclosed |
| US-9688960-B2 | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688960-B2 | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688960-B2 | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160010061-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL | 2016-01-14 | — | — | US | disclosed |
| US-20160010061-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL | 2016-01-14 | — | — | US | disclosed |
| US-20160010061-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | EASTERN VIRGINIA MEDICAL SCHOOL | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275591-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | NOX1, NOX3, NOXO1 | NOX4 5/4885CYBB 8/4885CYP3A4 4215/4885 |
| US-20160010061-A1 | METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1 | NOX1, NOX3, NOX4 | NOX4 3/4885CYBB 7/4885CYP3A4 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.